Therapeutic insulins and their large-scale manufacture

Biotechnological innovations over the past 25 years have underpinned the rapid development of a thriving biopharmaceutical sector. Therapeutic insulin remains one of the most commonly used products of pharmaceutical biotechnology and insulin-based products command annual global sales in excess of $4.5 billion. Innovations in its method of production and in particular the advent of engineered insulin analogues provide a fascinating insight into how scientific and technological advances have impacted upon the pharmaceutical biotechnology sector as a whole. Current insulin-based diabetes research is increasingly focused not on the insulin molecule per se, but upon areas such as the development of non-parenteral insulin delivery systems, as well as organ-/cell-based and gene therapy-based approaches to controlling the disease.

[1]  Per Balschmidt,et al.  Engineering-enhanced Protein Secretory Expression in Yeast with Application to Insulin* 210 , 2002, The Journal of Biological Chemistry.

[2]  H. Jun,et al.  Recent advances in insulin gene therapy for type 1 diabetes. , 2002, Trends in molecular medicine.

[3]  W. Cefalu.  Concept, strategies, and feasibility of noninvasive insulin delivery. , 2004, Diabetes care.

[4]  L. Thim,et al.  BIOSYNTHESIS OF HUMAN INSULIN IN YEAST VIA SINGLE-CHAIN PRECURSORS , 1987 .

[5]  O. Pillai,et al.  Insulin therapies - past, present and future. , 2001, Drug discovery today.

[6]  D. Owens,et al.  Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects. , 1988, BMJ.

[7]  K. Paulose.  History of insulin. , 1999, The Journal of the Association of Physicians of India.

[8]  T. Kjeldsen,et al.  Yeast secretory expression of insulin precursors , 2000, Applied Microbiology and Biotechnology.

[9]  G. Homandberg,et al.  Synthesis of peptide bonds by proteinases. Addition of organic cosolvents shifts peptide bond equilibria toward synthesis. , 1978, Biochemistry.

[10]  L. Heinemann,et al.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. , 2004, Diabetes.

[11]  R. Chance,et al.  Research, Development, Production, and Safety of Biosynthetic Human Insulin , 1993, Diabetes Care.

[12]  Gary Walsh,et al.  Biopharmaceuticals: Biochemistry and Biotechnology , 1998 .

[13]  Jeffrey,et al.  Role of C-terminal B-chain residues in insulin assembly : the structure of hexameric LysB 28 ProB 29-human insulin , 2004 .

[14]  A. Fisher,et al.  Crystalline insulin. , 1926, The Biochemical journal.

[15]  B. Zinman,et al.  Insulins today and beyond , 2001, The Lancet.

[16]  S. Efrat.  Generation of insulin-producing cells from stem cells for cell replacement therapy of type 1 diabetes. , 2004, The Israel Medical Association journal : IMAJ.

[17]  S. Clement,et al.  Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. , 2004, Metabolism: clinical and experimental.

[18]  R. Chance,et al.  Improving insulin therapy: achievements and challenges. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[19]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[20]  G. Leibowitz,et al.  Towards gene therapy of diabetes mellitus. , 1999, Molecular medicine today.

[21]  N. Ghilzai.  New Developments in Insulin Delivery , 2003 .

[22]  Carino,et al.  Oral insulin delivery. , 1999, Advanced drug delivery reviews.

[23]  J. Reig,et al.  Bio-engineering insulin-secreting cells from embryonic stem cells: A review of progress , 2003, Medical and Biological Engineering and Computing.

[24]  L. Thim,et al.  Human monocomponent insulin. Chemistry and characteristics. , 2009, Acta medica Scandinavica. Supplementum.

[25]  王姮,et al.  Inhaled insulin , 2005 .

[26]  L. Illum,et al.  Intranasal insulin delivery and therapy. , 1999, Advanced drug delivery reviews.

[27]  Chance Re,et al.  Improving Insulin Therapy: Achievements and Challenges , 1994 .

[28]  M. Rawlins,et al.  Inhaled insulin , 2006, The Lancet.

[29]  J. Sutcliffe,et al.  A History of Medicine: From Prehistory to the Year 2020 , 1992 .

[30]  J. J. Abel,et al.  Crystalline Insulin. , 1926, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Owens,et al.  Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes , 1990, The Lancet.

[32]  J. M. Beals,et al.  LYS(B28)PRO(B29)-HUMAN INSULIN , 1996 .

[33]  D. Nicol,et al.  Amino-Acid Sequence of Human Insulin , 1960, Nature.

[34]  H. Tsuzuki,et al.  Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulin , 1979, Nature.

[35]  S. Havelund,et al.  Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. , 1997, Journal of pharmaceutical sciences.

[36]  H. Sollinger,et al.  Hepatic Insulin Gene Therapy in Insulin‐Dependent Diabetes Mellitus , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  D. Owens,et al.  Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic Subjects , 1991, Diabetes Care.

[38]  C. H. Best,et al.  The internal secretion of the pancreas , 1922 .

[39]  R Langer,et al.  Responsive polymeric delivery systems. , 2001, Advanced drug delivery reviews.

[40]  A. Peck,et al.  In vitro-generation of surrogate islets from adult stem cells. , 2004, Transplant immunology.

[41]  D R Owens,et al.  Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.

[42]  G. Steil,et al.  Closed-loop insulin delivery-the path to physiological glucose control. , 2004, Advanced drug delivery reviews.

[43]  B. Zinman,et al.  Alternative routes of insulin delivery , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[44]  Tom L. Blundell,et al.  Insulin: The Structure in the Crystal and its Reflection in Chemistry and Biology by , 1972 .

[45]  Y. Bae,et al.  Cell transplantation for endocrine disorders. , 2000, Advanced drug delivery reviews.

[46]  T. Heise,et al.  Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. , 2004, Diabetes technology & therapeutics.

[47]  J. M. Beals,et al.  Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. , 1995, Structure.

[48]  L. Thim,et al.  Secretion and processing of insulin precursors in yeast. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[49]  U. Ribel,et al.  The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin , 2004, Pharmaceutical Research.

[50]  Ronald E. Chance,et al.  Insulin Lispro (Humalog) , 1999 .

[51]  J. Brange,et al.  Monomeric insulins obtained by protein engineering and their medical implications , 1988, Nature.

[52]  B. Riniker,et al.  Totalsynthese von Humaninsulin unter gezielter Bildung der Disulfidbindungen. Vorläufige Mitteilung , 1974 .

[53]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .